Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

Impurities & degradation products

An impurity or degradation product above its limit - other than nitrosamines. Unexpected substances in a batch can make it unsafe or less effective, even when the active ingredient is present.

704 FDA drug recalls with this cause, newest first.

Every drug has a specification for how much of each impurity or breakdown product it may contain. These recalls are lots that exceeded one of those limits - often a related compound formed during manufacturing or storage, or an out-of-specification result found during routine stability testing. Nitrosamine impurities are common enough to get their own category; everything else lands here.

Class III · Low risk

Hydralazine HCl Tablets

Failed Impurities/Degradation Specifications; during routine stability testing for impurities.

Terminated Impurity / degradation The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories NDC 0904-6441-61 D-0045-2025
Class II · Moderate risk

Ibuprofen 800mg

Failed Impurities/Degradation Specifications: Product failed impurity specifications at the 18-month stability testing.

Ongoing Impurity / degradation Direct Rx NDC 61919-0621-15 D-0041-2025
Class II · Moderate risk

Ibuprofen Tablets

Failed Impurities/Degradation Specifications - at 18-month Stability testing

Ongoing Impurity / degradation Preferred Pharmaceuticals, Inc. NDC 68788-9110-03 D-0647-2024
Class III · Low risk

Hydrocortisone 1% & Acetic Acid 2% Otic Solution

Failed Impurities/Degradation Specifications: Out-of-specification results obtained for related impurities and slightly lower than the established level of the Hydrocortisone Assay obtained during stability testing.

Completed Impurity / degradation Taro Pharmaceuticals U.S.A., Inc. NDC 51672-3007-01 D-0633-2024
Class II · Moderate risk

IBU Ibuprofen Tablets

Failed impurities/degradation specifications: results for unknown impurity, were 0.13% and 0.11% respectively, exceeding the 0.10% specification limit.

Ongoing Impurity / degradation Dr. Reddy's Laboratories, Inc. NDC 55111-682-01 D-0646-2024
Class II · Moderate risk

IBU Ibuprofen Tablets

Failed impurities/degradation specifications: results for unknown impurity, were 0.13% and 0.11% respectively, exceeding the 0.10% specification limit.

Ongoing Impurity / degradation Dr. Reddy's Laboratories, Inc. NDC 55111-683-01 D-0645-2024
Class II · Moderate risk

IBU Ibuprofen Tablets

Failed impurities/degradation specifications: results for unknown impurity, were 0.13% and 0.11% respectively, exceeding the 0.10% specification limit.

Ongoing Impurity / degradation Dr. Reddy's Laboratories, Inc. NDC 55111-684-01 D-0644-2024
Class II · Moderate risk

Fludrocortisone Acetate Tablets

Failed Impurities/Degradation Specifications: Product is being recalled due to API related substances and unknown impurities that are above the specification limits.

Ongoing Impurity / degradation Teva Pharmaceuticals USA, Inc NDC 0555-0997-02 D-0601-2024
Class III · Low risk

Diflorasone Diacetate Ointment

Failed Impurities/Degradation Specifications: The impurity results at 12 months stability testing,did not conform to the specification limit.

Ongoing Impurity / degradation Rising Pharma Holding, Inc. NDC 64980-124-60 D-0599-2024
Class III · Low risk

Eszopiclone Tablets

Failed Impurities/Degradation Specifications: Related Substances

Ongoing Impurity / degradation Dr. Reddy's Laboratories, Inc. NDC 55111-629-30 D-0581-2024
Class II · Moderate risk

Cardura XL

Failed Impurities/Degradation Specifications

Completed Impurity / degradation Viatris Inc NDC 0049-2080-10 D-0603-2024
Class II · Moderate risk

Cardura XL

Failed Impurities/Degradation Specifications

Completed Impurity / degradation Viatris Inc NDC 0049-2040-10 D-0602-2024
Class II · Moderate risk

Ful-Glo

Failed Impurities/Degradation Specifications: The Active Pharmaceutical Ingredient (API) used in the product is not being manufactured to the current USP monograph in regard to Unspecified Impurities.

Ongoing Impurity / degradation Nomax Inc NDC 17478-404-01 D-0465-2024
Class II · Moderate risk

Ful-Glo

Failed Impurities/Degradation Specifications: The Active Pharmaceutical Ingredient (API) used in the product is not being manufactured to the current USP monograph in regard to Unspecified Impurities.

Ongoing Impurity / degradation Nomax Inc NDC 17478-403-03 D-0464-2024